# Ultrasound-guided pulsed radiofrequency versus perineural platelet rich plasma injection for the treatment of idiopathic carpal tunnel syndrome: a prospective randomized controlled study

**Authors:** Engi Yousry Hashem, Faten Saeed Shamandy, Ahmed Fawzy Elmulla, Magdy AbdelAziz Mansour

PMC · DOI: 10.1186/s12871-025-03257-x · BMC Anesthesiology · 2025-08-13

## TL;DR

This study compares ultrasound-guided treatments for carpal tunnel syndrome, finding that pulsed radiofrequency and steroids work better than platelet-rich plasma.

## Contribution

A novel prospective randomized controlled trial comparing pulsed radiofrequency, steroids, and platelet-rich plasma for carpal tunnel syndrome.

## Key findings

- PRF and steroid groups showed greater pain and function improvement than PRP.
- All groups improved significantly in pain, function, and nerve measurements.
- PRP had the least improvement compared to other treatments.

## Abstract

Carpal tunnel syndrome (CTS) is the most common focal mononeuropathy caused by the compression of the median nerve within the carpal tunnel. Ultrasound-guided hydrodissection with corticosteroids, platelet-rich plasma injection, and median nerve pulsed radiofrequency are all potential treatments for relieving symptoms of CTS in mild and moderate cases, comparison between their clinical outcomes is yet to be studied.The primary outcome was pain measured by Visual Analog Scale (VAS). The secondary outcomes included functional outcome evaluated by the Boston Carpal Tunnel Questionnaire (BCTQ), Nerve Conduction Velocity (NCV) and median nerve cross-sectional area (CSA).

This prospective, double-blinded, randomized controlled study was conducted on Seventy-five patients diagnosed with mild to moderate CTS, they were randomly allocated into three equal groups. The control group received a median nerve perineural injection of bupivacaine with methylprednisolone. The PRF group received median nerve pulsed radiofrequency in addition to bupivacaine. Finally, the PRP group received a perineural injection of platelet-rich plasma.

Were conducted at specific time intervals: before the intervention, at one week, two months, and four months post-intervention for VAS, BCTQ, and CSA. NCV was only evaluated before the intervention and after four months.

All patients experienced a statistically significant improvement in pain, symptoms, function, CSA of the median nerve and NCV following intervention. The PRF and steroid groups exhibited greater improvements than the PRP group. The PRP group showed the least improvement compared to the other two groups.

Short study period, single centred study.

The current study suggests that ultrasound-guided hydrodissection of the median nerve, with local anesthetic/steroids or PRP and PRF are effective in alleviating pain and improving the functional outcome. Nevertheless, it was revealed that PRF and steroid injection were more efficacious in enhancing short term functional outcomes compared to PRP injection.

The study was retrospectively registered in the “Clinical Trials Library for Protocol Registration and Results System” under NCT05053477 on September 11, 2021.

The online version contains supplementary material available at 10.1186/s12871-025-03257-x.

## Linked entities

- **Chemicals:** bupivacaine (PubChem CID 2474), methylprednisolone (PubChem CID 6741)
- **Diseases:** carpal tunnel syndrome (MONDO:0007275)

## Full-text entities

- **Genes:** SPNS1 (SPNS lysolipid transporter 1, lysophospholipid) [NCBI Gene 83985] {aka HSpin1, LAT, PP2030, SLC62A1, SLC63A1, SPIN1}, BDNF (brain derived neurotrophic factor) [NCBI Gene 627] {aka ANON2, BULN2}, NGF (nerve growth factor) [NCBI Gene 4803] {aka Beta-NGF, HSAN5, NGFB}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, F2 (coagulation factor II, thrombin) [NCBI Gene 2147] {aka PT, RPRGL2, THPH1}, IGF1 (insulin like growth factor 1) [NCBI Gene 3479] {aka IGF, IGF-I, IGFI, MGF}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, COL3A1 (collagen type III alpha 1 chain) [NCBI Gene 1281] {aka EDS4A, EDSVASC, PMGEDSV}, COL1A2 (collagen type I alpha 2 chain) [NCBI Gene 1278] {aka EDSARTH2, EDSCV, OI4}, TTR (transthyretin) [NCBI Gene 7276] {aka AMYLD1, ATTR, CTS, CTS1, HEL111, HsT2651}, COL1A1 (collagen type I alpha 1 chain) [NCBI Gene 1277] {aka CAFYD, EDSARTH1, EDSC, OI1, OI2, OI3}, FN1 (fibronectin 1) [NCBI Gene 2335] {aka CIG, ED-B, FINC, FN, FNZ, GFND}, FOS (Fos proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 2353] {aka AP-1, C-FOS, p55}, VTN (vitronectin) [NCBI Gene 7448] {aka V75, VN, VNT}
- **Diseases:** Ganglion cyst (MESH:D045888), numbness (MESH:D006987), mononeuropathy (MESH:D020422), tunnel (MESH:D020425), neuropathies (MESH:D009422), NCV (MESH:C564269), Carpal Tunnel Syndrome (MESH:D002349), inflammation (MESH:D007249), acromegaly (MESH:D000172), allergic reactions (MESH:D004342), hypopigmentation (MESH:D017496), atrophy (MESH:D001284), diabetes mellitus (MESH:D003920), hydrodissection of the median nerve (MESH:D020423), tumor (MESH:D009369), peripheral nerve injuries (MESH:D059348), thyroid disease (MESH:D013959), edema (MESH:D004487), compression neuropathy (MESH:D009408), neuropathic pain (MESH:D009437), fibrosis (MESH:D005355), pigmentation (MESH:D010859), CSA (MESH:C537866), ischemia (MESH:D007511), systemic disease (MESH:D034721), muscle atrophy (MESH:D009133), neuroinflammatory (MESH:D000090862), Pain (MESH:D010146), tenosynovitis (MESH:D013717)
- **Chemicals:** steroid (MESH:D013256), blood sugar (MESH:D001786), citrate (MESH:D019343), methylprednisolone (MESH:D008775), dextrose (MESH:D005947), paracetamol (MESH:D000082), triamcinolone acetonide (MESH:D014222), dexamethasone (MESH:D003907), BCTQ (-), bupivacaine (MESH:D002045)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12351916/full.md

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12351916/full.md

---
Source: https://tomesphere.com/paper/PMC12351916